Key result
Combined use of linezolid and SSRIs/SNRIs did not significantly increase serotonin syndrome incidence compared with linezolid monotherapy (1.1% vs 0.4%; RR 3.00; 95% CI 0.19-47.45; P=0.438).
Why the study?
Does the combined use of linezolid and SSRIs or SNRIs increase the incidence of serotonin syndrome compared to linezolid monotherapy in adult inpatients?
Population
348 adult inpatients admitted to the University of Iowa Hospitals and Clinics who received linezolid between…
Comparison
Linezolid administered in combination with a… vs Linezolid monotherapy, matched 3:1 by age and…
Design
Case-control
Authors
Loading...
Reassures against routine avoidance in inpatients; leaves open confirmation of safety in larger prospective studies.
Case-Control (n=348)
No
Does the combined use of linezolid and SSRIs or SNRIs increase the incidence of serotonin syndrome compared to linezolid monotherapy in adult inpatients?
Relative Risk: 3 (95% CI 0.19–47.45)
Absolute Event Rate: 1.1% vs 0.4%
p-value: p=0.438
The combination of linezolid with SSRIs or SNRIs does not significantly increase the risk of serotonin syndrome compared to linezolid monotherapy, with the overall incidence remaining very low.
Karkow et al. (2017) conducted a case-control in Patients receiving linezolid (n=348). Linezolid combined with SSRIs or SNRIs vs. Linezolid monotherapy was evaluated on Diagnosis of serotonin syndrome (RR 3.00, 95% CI 0.19-47.45, p=0.438). Combined use of linezolid and SSRIs/SNRIs did not significantly increase serotonin syndrome incidence compared with linezolid monotherapy (1.1% vs 0.4%; RR 3.00; 95% CI 0.19-47.45; P=0.438).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: